

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete

Application Number

~~PCT/FR99/01489~~ 09 | 720,569

Filing Date

~~Concurrently herewith~~ 2-22-01

First Named Inventor

Philippe Douaire et al.

Group Art Unit

~~To be assigned~~ — 1761

Examiner Name _____

~~To be assigned~~ *C. b. in*

Sheet	1	of	2
-------	---	----	---

Attorney Docket Number

33339/207111

[illegible]

Class/Kubelass

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code (if known) ⁵				
<i>sec</i>	1	FR	2137872		Unilever NV	12-29-1972	—	
<i>sec</i>	2	EP	0 214834		International Minerals and Chemical Corp.	03-18-1987	—	
<i>sec</i>	3	EP	0 259219		Universite de Montreal	03-09-1988	—	
<i>sec</i>	4	DE	4342146	C1	Notter GMBH	07-06-1995	—	

Examiner
Signature

ARTHUR L. CORBIN

Date
Considered

7-15-03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	33339/207111
-------	---	----	---	------------------------	--------------

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials

Cite
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.

T

5

J. P. CLEAVE; *Some geometrical considerations concerning the design of tablets*; J. Pharm. Pharmacol.; 1965; pages 698 – 702; Vol. 17; BNSDOCID; XP002096313.

6

P.H. LIST, et al.; *Hagers Handbuch der Pharmazeutischen Praxis*; Springer Verlag; 1971; page 691; Figure 388A; Exemple Q; XP002096314; Berlin Heidelberg/New York.

7

MARIA EDVIGE SANGALLI, PAOLO GIUNCHEDI, LAURETTA MAGGI, UBALDO CONTE, ANDREA GAZZANIGA; *Inert Monolithic Device with a Central Hole for Constant Drug Release*; European Journal of Pharmaceutics and Biopharmaceutics; December 1994; Pages 370 – 373; Vol. 40, No. 6; XP000480157; Stuttgart, Germany.

Examiner
Signature

ARTHUR L. CORBIN

Date
Considered

7-15-03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.